Company intelligence / Profile preview
Antelope Surgical Solutions
- Ownership
- Private
- Development stage
- Other
Overview
Clinical-stage company developing dual-purpose radiofluorescent agents combining therapeutic isotopes with fluorescent imaging. First-in-class PSMA-targeted AS1986NS received FDA IND clearance in November 2024, with trials starting summer 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesRadioligand-targeted therapyFluorescence-guided surgery agents
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Antelope Surgical Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antelope Surgical Solutions.